intellia logo
Opening a new era of medicine
Read about our groundbreaking clinical data using CRISPR genome editing
News Update
June 26, 2021
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
Overview

Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.

Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.

Learn About Our Mission
Programs & Pipeline

Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.

Join Us.
See how you can change life stories with genome editing
Learn More
Full-Spectrum Blog
Opening a New Era of Medicine
Opening a New Era of Medicine
Read the full article
Follow Us on Social Media
July 7, 2021

Do you want to be on a team that is making history? We are growing our medical group! Our team of physician-researchers are looking for Sr. Medical Directors to join Intellia’s team. Learn more and apply today! https://t.co/fpNp8aEgxC #CRISPR #biotechjobs https://t.co/pR18nbFc98

View on Twitter
July 5, 2021

From July 5 – July 9, Intellia will be closed for our annual summer shutdown. This is just one of the many great employee benefits that we offer! Check out our other benefits here: https://t.co/fpNp8aEgxC #IamIntellia #CRISPR #genomeediting https://t.co/EpNHKMe77j

View on Twitter
Menu